BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26521987)

  • 21. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
    Bjorklund CC; Kang J; Amatangelo M; Polonskaia A; Katz M; Chiu H; Couto S; Wang M; Ren Y; Ortiz M; Towfic F; Flynt JE; Pierceall W; Thakurta A
    Leukemia; 2020 Apr; 34(4):1197-1201. PubMed ID: 31719682
    [No Abstract]   [Full Text] [Related]  

  • 22. What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
    Costa BA; Mouhieddine TH; Richter J
    Target Oncol; 2022 Jul; 17(4):383-405. PubMed ID: 35771402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
    Kim GW; Yoo J; Won HR; Yeon SK; Lee SW; Lee DH; Jeon YH; Kwon SH
    Leuk Res; 2020 Aug; 95():106398. PubMed ID: 32512378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recent topics in IMiDs and cereblon].
    Ito T; Handa H
    Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide.
    Tateno S; Iida M; Fujii S; Suwa T; Katayama M; Tokuyama H; Yamamoto J; Ito T; Sakamoto S; Handa H; Yamaguchi Y
    Sci Rep; 2020 Mar; 10(1):4012. PubMed ID: 32132601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
    Qian X; Dimopoulos MA; Amatangelo M; Bjorklund C; Towfic F; Flynt E; Weisel KC; Ocio EM; Yu X; Peluso T; Sternas L; Zaki M; Moreau P; Thakurta A
    Leuk Lymphoma; 2019 Feb; 60(2):462-470. PubMed ID: 30068263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
    Kuwahara-Ota S; Shimura Y; Steinebach C; Isa R; Yamaguchi J; Nishiyama D; Fujibayashi Y; Takimoto-Shimomura T; Mizuno Y; Matsumura-Kimoto Y; Tsukamoto T; Chinen Y; Kobayashi T; Horiike S; Taniwaki M; Gütschow M; Kuroda J
    Br J Haematol; 2020 Dec; 191(5):784-795. PubMed ID: 32558939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A New Strategy for the Old Challenge of Thalidomide: Systems Biology Prioritization of Potential Immunomodulatory Drug (IMiD)-Targeted Transcription Factors.
    Kowalski TW; Feira MF; Lord VO; Gomes JDA; Giudicelli GC; Fraga LR; Sanseverino MTV; Recamonde-Mendoza M; Schuler-Faccini L; Vianna FSL
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive assessment and meta-analysis of the association between CTNNB1 polymorphisms and cancer risk.
    Li Y; Zhang F; Yang D
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28963373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review].
    Fan WJ; Fan ZQ; Yang MJ; Pan YZ; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1240-1243. PubMed ID: 30111438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
    Hirano M; Imai Y; Kaito Y; Murayama T; Sato K; Ishida T; Yamamoto J; Ito T; Futami M; Ri M; Yasui H; Denda T; Tanaka Y; Ota Y; Nojima M; Kamikubo Y; Gotoh N; Iida S; Handa H; Tojo A
    J Exp Clin Cancer Res; 2021 Mar; 40(1):110. PubMed ID: 33757580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
    Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
    Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients.
    Barankiewicz J; Szumera-Ciećkiewicz A; Salomon-Perzyński A; Wieszczy P; Malenda A; Garbicz F; Prochorec-Sobieszek M; Misiewicz-Krzemińska I; Juszczyński P; Lech-Marańda E
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34207079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo.
    Sha Y; Wu J; Paul B; Zhao Y; Mathews P; Li Z; Norris J; Wang E; McDonnell DP; Kang Y
    Cancer Lett; 2022 Oct; 545():215832. PubMed ID: 35872263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutral tumor evolution in myeloma is associated with poor prognosis.
    Johnson DC; Lenive O; Mitchell J; Jackson G; Owen R; Drayson M; Cook G; Jones JR; Pawlyn C; Davies FE; Walker BA; Wardell C; Gregory WM; Cairns D; Morgan GJ; Houlston RS; Kaiser MF
    Blood; 2017 Oct; 130(14):1639-1643. PubMed ID: 28827410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation.
    Shi Q; Chen L
    J Immunol Res; 2017; 2017():9130608. PubMed ID: 28894755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
    Haertle L; Barrio S; Munawar U; Han S; Zhou X; Vogt C; Fernández RA; Bittrich M; Ruiz-Heredia Y; Da Viá M; Zovko J; Garitano-Trojaola A; Bolli N; Ruckdeschel A; Stühmer T; Chatterjee M; Kull M; Krönke J; Agirre X; Martin-Subero JI; Raab P; Einsele H; Rasche L; Martinez-Lopez J; Haaf T; Kortüm KM
    Blood; 2021 Nov; 138(18):1721-1726. PubMed ID: 34115836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
    Yau P; Jimenez-Zepeda VH; Bailey K; Duggan P; Tay J; Bahlis NJ; Neri P; McCulloch S
    Leuk Lymphoma; 2019 Dec; 60(13):3199-3203. PubMed ID: 31190585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPRing the CRL4
    Neri P
    Blood; 2018 Sep; 132(12):1219-1220. PubMed ID: 30237253
    [No Abstract]   [Full Text] [Related]  

  • 40. Single nucleotide polymorphisms within the Wnt pathway predict the risk of bone metastasis in patients with non-small cell lung cancer.
    Xu Y; Li H; Weng L; Qiu Y; Zheng J; He H; Zheng D; Pan J; Wu F; Chen Y
    Aging (Albany NY); 2020 May; 12(10):9311-9327. PubMed ID: 32453708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.